Analyst Price Targets — APGE
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 24, 2026 1:33 pm | — | Stifel Nicolaus | $135.00 | $132.97 | TheFly | Apogee Therapeutics downgraded to Hold from Buy at Stifel |
| June 24, 2026 8:12 am | Joseph Catanzaro | Mizuho Securities | $135.00 | $132.88 | StreetInsider | Mizuho Downgrades Apogee Therapeutics Inc (APGE) to Neutral |
| June 23, 2026 10:49 am | — | RBC Capital | $135.00 | $132.55 | TheFly | Apogee Therapeutics downgraded to Sector Perform from Outperform at RBC Capital |
| June 23, 2026 9:21 am | — | UBS | $135.11 | $132.55 | TheFly | Apogee Therapeutics downgraded to Neutral from Buy at UBS |
| June 22, 2026 7:40 pm | David Hoang | Deutsche Bank | $135.00 | $132.55 | TheFly | Apogee Therapeutics downgraded to Hold from Buy at Deutsche Bank |
| June 22, 2026 3:54 pm | — | Craig-Hallum | $135.11 | $132.65 | TheFly | Apogee Therapeutics downgraded to Hold from Buy at Craig-Hallum |
| June 8, 2026 9:19 am | Brian Abrahams | RBC Capital | $97.00 | $86.92 | StreetInsider | Apogee Therapeutics Inc (APGE) PT Raised to $97 at RBC Capital |
| May 28, 2026 12:05 pm | — | Goldman Sachs | $89.00 | $77.50 | TheFly | Apogee Therapeutics moved to Neutral at Goldman Sachs |
| May 27, 2026 4:51 pm | Danielle Brill | Truist Financial | $81.00 | $78.07 | TheFly | Apogee Therapeutics price target lowered to $81 from $83 at Truist |
| May 27, 2026 12:45 pm | — | Wedbush | $135.00 | $81.73 | TheFly | Apogee Therapeutics price target raised to $135 from $120 at Wedbush |
Latest News for APGE
Big Pharma has a $300 billion problem, and biotech developers with promising drugs are becoming the fix. Major drugmakers are spending at a pace not seen since 2019 to replace medicines that will soon lose patent protection.
Are AVB, LPRO, APGE, TMHC Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, July 6, 2026
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
MILWAUKEE, July 02, 2026 (GLOBE NEWSWIRE) -- Ademi LLP is investigating Apogee (NASDAQ: APGE) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with CRH. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.
MILWAUKEE, July 02, 2026 (GLOBE NEWSWIRE) -- Ademi LLP is investigating Apogee (NASDAQ: APGE) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with CRH.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for APGE.
U.S. House Trading
No House trades found for APGE.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.